Goldman Sachs
INSY

Goldman Sachs’s Insys Therapeutics, Inc. INSY Stock Holding History

Goldman Sachs’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-2,500
Closed -$15K – 6212
2018
Q1 		$15K Buy
+2,500
New +$20.6K ﹤0.01% 5712
2017
Q2 		– Sell
-92,900
Closed -$976K – 7097
2017
Q1 		$976K Buy
+92,900
New +$990K ﹤0.01% 4396
2016
Q3 		– Sell
-604,000
Closed -$7.82M – 7294
2016
Q2 		$7.82M Buy
604,000
+420,200
+229% +$6.12M ﹤0.01% 2512
2016
Q1 		$2.94M Buy
183,800
+89,000
+94% +$1.69M ﹤0.01% 3154
2015
Q4 		$2.71M Sell
94,800
-1,054,700
-92% -$29.2M ﹤0.01% 3362
2015
Q3 		$32.7M Buy
1,149,500
+1,046,500
+1,016% +$38.5M 0.01% 1353
2015
Q2 		$3.7M Buy
103,000
+67,800
+193% +$2.11M ﹤0.01% 3217
2015
Q1 		$1.02M Sell
35,200
-64,800
-65% -$1.71M ﹤0.01% 4456
2014
Q4 		$2.11M Buy
+100,000
New +$1.98M ﹤0.01% 3786

Other funds holding INSY

California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $39.9B AUM 29.7% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

Goldman Sachs's INSY Position: Q2 2019 in Review

Goldman Sachs sold out of Insys Therapeutics, Inc. (INSY) in Q2 2019, closing a stake of 157,592 shares — an estimated $728K sold.

Goldman Sachs first reported a position in INSY in Q4 2013 and held it in 22 quarters. The position peaked at $20.3M in Q3 2015. 16 funds tracked by Wall St. Rank hold INSY as of Q2 2019.

  • Goldman Sachs reported no remaining Insys Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
  • Goldman Sachs sold 157,592 Insys Therapeutics, Inc. shares in Q2 2019, an estimated $728K.
  • Goldman Sachs first reported a position in Insys Therapeutics, Inc. in Q4 2013 and held it in 22 quarters.
  • Goldman Sachs's Insys Therapeutics, Inc. position peaked at $20.3M in Q3 2015.
  • 16 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q2 2019.

Based on Goldman Sachs's 13F filing for Q2 2019, filed 14 Aug 2019.